Get a Call

Market News

  • 04


    Dr. Reddy`s gains after announcing re-launch of Zenatane

    The announcement was after market hours on Monday, 3 June 2019.

    Meanwhile the S&P BSE Sensex was down 29.92 points or 0.07% at 40,237.70.

    On BSE, 9373 shares were traded so far on the counter as against the 2-week average of 27,000 shares. The stock had hit a 52-week high of Rs 2,965.20 on 2 May 2019 and a 52-week low of Rs 1,950.30 on 6 June 2018.

    Dr. Reddy`s Laboratories announced the relaunch of Zenatane (lsotretinoin capsules), 10 mg, 20 mg, 30 mg and 40 mg, a therapeutic equivalent generic version of Accutane, which was approved by the US Food and Drug Administration (USFDA).

    According to IQVIA Health, the Zenatane (lsotretinoin capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg brand and generic had US sales of approximately $525 million MAT for the most recent twelve months ending in March 2019.

    Dr. Reddy`s Laboratories` consolidated net profit increased 67.4% to Rs 455.40 crore on 13.6% increase in net sales to Rs 4,016.60 crore in Q4 March 2019 as against Q4 March 2018.

    Dr Reddy`s Laboratories (DRL) is an integrated global pharmaceutical company.

    Powered by Capital Market - Live News

NIFTY 11887.45 img 39.90

SENSEX 39717.63 img 125.55

GOLD 33885.00

SILVER 37647.00

1 USD / INR 69.22

Attention Investors! "Prevent Unauthorised Transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of Investors."           Attention Investors! "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL/CDSL on the same day. Issued in the interest of investors."           "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."           "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."           "As per SEBI guidelines, old DIS cannot be accepted for execution of instruction with effect from 07-01-2016. Kindly submit requisition slip / letter for issuance of new DIS booklet at our corporate office address to avoid rejection of your instruction(s) on or after 07-01-2016.”            "In accordance with the Union Budget 2017-18 announcement, SEBI has advised to link Aadhar with individual demat accounts. Kindly submit details of Aadhar number along with copy of Aadhar Card.”          

Copyright © 2019. All Rights Reserved. Indiabulls Ventures Limited. | Cookie Policy | Bechmark Rates | Disclaimer | Terms and Condition | Blog

Indiabulls Ventures Limited. [Corporate Identification Number for IVL: L74999DL1995PLC069631]
SEBI Reg No: INZ000007534 | NSE Membership No: 08756 [CM, FNO, CDS] | BSE Membership No: 907 [CM, FNO]
Indiabulls Securities Limited (Formerly known as Indiabulls Commodities Limited) [Corporate Identification Number for ISL: U74999DL2003PLC122874]
SEBI Reg No: INZ000036136 | MCX: MEMBER CODE: 12835 | NCDEX: MEMBER CODE: 10
Registered office address: M - 62 & 63, First Floor, Connaught Place, New Delhi - 110001.
Correspondence office address: Indiabulls House, 448 – 451, Udyog Vihar, Phase – V, Gurgaon – 122016, Haryana.
Site best viewed in IExplorer 10+ | Chrome | Firefox